Literature DB >> 6339312

Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.

R M Pérez-Ayuso, V Arroyo, R Planas, J Gaya, F Bory, A Rimola, F Rivera, J Rodés.   

Abstract

Loop and distal diuretics are the basic drugs for the treatment of ascites. Although pharmacologic studies indicate that the natriuretic potency of loop diuretics is much greater than that of distal diuretics, there are no studies comparing the efficacy of these drugs in cirrhosis. Forty nonazotemic cirrhotic patients with ascites and avid sodium retention were randomly allocated into two groups. Group 1 contained 21 patients treated with furosemide; group 2 contained 19 patients treated with spironolactone. The initial doses were 80 and 150 mg/day, respectively. These doses were increased to 160 and 300 mg/day, respectively, if there was no response. Cases not responding to furosemide and spironolactone were later treated with spironolactone and furosemide, respectively. In group 1, 11 of the 21 patients responded to furosemide, while in group 2, 18 of the 19 patients responded to spironolactone (p less than 0.01). Of the 10 patients in group 1 not responding to furosemide, 9 responded later to spironolactone. The diuretic response to furosemide and spironolactone was related to the activity of the renin-aldosterone system. Patients with higher renin and aldosterone did not respond to furosemide and required 300 mg/day of spironolactone to achieve a diuretic response. These results indicate that (a) at the dosages used in the study, spironolactone is more effective than furosemide in nonazotemic cirrhosis with ascites, and (b) the activity of the renin-aldosterone system influences the diuretic response to furosemide and spironolactone in these patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339312

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  50 in total

1.  [6 years of the International Union of Societies of Immunology. Presidential report (Brighton 1974)].

Authors:  B Cinader
Journal:  Medicina (B Aires)       Date:  1975 Jul-Aug       Impact factor: 0.653

2.  Hepatobiliary quiz-7 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-09

Review 3.  Treatment and management of ascites and hepatorenal syndrome: an update.

Authors:  Kurt Lenz; Robert Buder; Lisbeth Kapun; Martin Voglmayr
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

Review 4.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

5.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

6.  A dedicated paracentesis clinic decreases healthcare utilization for serial paracenteses in decompensated cirrhosis.

Authors:  Yao-Wen Cheng; Kumar Sandrasegaran; Katherine Cheng; Angela Shah; Marwan Ghabril; William Berry; Craig Lammert; Naga Chalasani; Eric S Orman
Journal:  Abdom Radiol (NY)       Date:  2018-08

Review 7.  Ascites in Children.

Authors:  Ashish Bavdekar; Nitin Thakur
Journal:  Indian J Pediatr       Date:  2016-06-09       Impact factor: 1.967

8.  Prediction of diuretic mobilization of cirrhotic ascites by pretreatment fractional sodium excretion.

Authors:  H Knauf; E Wenk; J Schölmerich; K J Goerg; W Gerok; H G Leser; E Mutschler
Journal:  Klin Wochenschr       Date:  1990-06-05

9.  Continuous furosemide infusion in the management of ascites.

Authors:  Nicholas A Rogers; Samir Gupta; Jennifer A Cuthbert
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

10.  Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.

Authors:  João Pedro Ferreira; Nicolas Girerd; Pedro Bettencourt Medeiros; Mário Santos; Henrique Cyrne Carvalho; Paulo Bettencourt; David Kénizou; Javed Butler; Faiez Zannad; Patrick Rossignol
Journal:  Clin Res Cardiol       Date:  2015-11-28       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.